Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO 2018 | ARROW: once vs. twice weekly carfilzomib for MM

After promising results from the CHAMPION-1 study (NCT01677858), which increased median progression-free survival to more than 1 year for relapsed/refractory multiple myeloma (MM) patients with a once-weekly therapy of carfilzomib and dexamethasone (Kd), the ARROW trial (NCT02412878) was set up to investigate whether Kd treatment was more effective with a once- or twice-weekly dose. Results from the trial were presented at the American Society of Oncology (ASCO) 2018 Annual Meeting ,held in Chicago, IL, with patient outcomes far improved for those receiving once-weekly therapy as opposed to twice. In this interview, Maria-Victoria Mateos, MD, PhD, from the University Hospital of Salamanca, Salamanca, Spain, provides insights into the trial’s rationale, highlighting the key findings and next steps.